Heparins and its derivatives, traditionally used as anticoagulants, have recently emerged as attractive compounds for selectin inhibition showing promising antimetastatic activity through disruption of P- and L-selectin-mediated adhesion of tumor cells (96). The gene discussed is SELL; the disease is neoplasm.